The Top Line-logo

The Top Line

Business & Economics Podcasts

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

Location:

United States

Description:

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning.

Language:

English


Episodes

Breaking down Eli Lilly’s ESG formula

2/23/2024
This week on “The Top Line,” we explore the impact of environmental, social and governance measures, commonly known as ESG, on the pharmaceutical industry. Fraiser Kansteiner of Fierce Pharma engages in a conversation with Jim Greffet, Head of ESG Strategy at Eli Lilly, to gain insights. Greffet makes a compelling business case for integrating ESG into the core of drugmakers' DNA. He also discusses Eli Lilly’s specific ESG initiatives, illustrating how these strategies connect to the company’s extensive history. To learn more about the topics in this episode: Patient groups want pharma to improve on ESG—and are pushing for a seat at the tableSetting sights on suppliers: How biopharma is tackling the environment in its ESG commitmentsSeeing green, AstraZeneca lays down £100M for 15-year renewable gas project in UKGilead receives awards, pledges commitment to COVID, the environment and inclusion in 2023 See omnystudio.com/listener for privacy information.

Duration:00:23:16

Gene editing's next act

2/16/2024
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. In the wake of these developments, new biotech companies are springing up spurred by advancements that redefine what conditions might soon become treatable. One contender in this rapidly changing landscape is Verve Therapeutics. This week on "The Top Line," Fierce Biotech’s Max Bayer sits down with the company’s CEO Sekar Kathiresan, M.D., to discuss how Verve intends to distinguish itself. They also chat about what drove Dr. Kathiresan to biotech after more than 20 years as a cardiologist and geneticist. To learn more about the topics in this episode: Verve Therapeutics unveils its lead program—a one-and-done treatment for genetic high cholesterolLilly beams up Verve gene therapy programs for $600M from deal-hungry BeamVerve shows base editing works in humans in first clinical data—and is punished by investorsVerve's base editing hold lifted, starting a thaw on a regulatory blockade that sent peers ex-US See omnystudio.com/listener for privacy information.

Duration:00:25:44

The most anticipated drug launches of 2024

2/9/2024
This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. To learn more about the topics in this episode: Top 10 most anticipated drug launches of 2024BMS unwraps $14B deal for Karuna, adding a schizophrenia drug awaiting FDA OKBristol Myers Squibb has targeted launch plan for ‘multi-billion-dollar opportunity’ in Karuna schizophrenia drugMeet Madrigal Pharmaceuticals, which wants to be your liver's No. 1 fan See omnystudio.com/listener for privacy information.

Duration:00:11:06

[Sponsored] Turning information into outcomes with MedThink Communications

2/5/2024
Should physicians consider the psychological status of patients more when developing and delivering treatment plans? What knowledge barriers are there to this? And how can these barriers be overcome? These questions lie at the heart of what John Kane has been pursuing as a healthcare communications and education expert for more than 30 years. As Managing Director of MedThink Communications, having run his own agency for 17 years, he works with the simple mission to "turn information into outcomes." In this episode of The Top Line podcast, John explores the link between a proper understanding of psychological factors and likely success of treatments. The conversation then moves on to discussing some of the key challenges faced by the medical industry in leveling the playing field between biological and psychological knowledge. Effective education and communication, he says, are a fundamental part of any solution. Want to hear more from John? Listen to the podcast today. See omnystudio.com/listener for privacy information.

Duration:00:20:06

[Sponsored] Talking technology and collaboration with Cytiva

2/5/2024
In this episode, Dr. Beate Mueller-Tiemann, Chief Technology Officer at Cytiva, joins Fierce Life Sciences’s Stephanie Butler. Having spent almost all of her career working within large pharmaceutical enterprises such as Sanofi and Bayer, Beate made the switch to Cytiva in the early part 2023. Her role at Cytiva involves overseeing teams which create and bring high-quality products and innovative manufacturing and R&D processes closer to patients. Beate also keenly supports female talents through participation in mentoring programs. Additionally, she is a member of FiDAR, an association which seeks to increase the representation of women on German corporate boards. During the conversation, Beate discusses her passion for technology and how her career has been defined by working with technology to bring innovation and treatments to patients and improve health outcomes. She also touches on the ongoing work Cytiva is engaged in, as well as the importance of collaboration in driving R&D progress. Tune in to the podcast to learn more. Check out this year's Fierce 50 honorees: https://fierce50.fiercelifesciences.com/ See omnystudio.com/listener for privacy information.

Duration:00:06:51

Navigating the future of medical AI

2/2/2024
While generative AI has dominated the spotlight in the past year, machine learning programs have already been significantly impacting patients and physicians for several years. The question now arises: how will the emergence of programs like ChatGPT, coupled with increasing calls to scrutinize their safety, influence the adoption of new AI programs and diagnostics in healthcare? This week on “The Top Line,” Fierce’s Conor Hale interviews Peter Shen, the North American head of digital health at Siemens Healthineers, to explore what developers and regulators can do to ensure transparency in medical AI. He also dives into how the field could potentially benefit from a 21st-century update to the Hippocratic Oath. To learn more about the topics in this episode: 2024 forecast: Will generative AI find what it needs to deliver for patients?FDA to form advisory committee for digital health and AIUS government to launch AI Safety Institute, develop standards for biotech R&DBiden to sign sweeping executive order pursuing 'safe, secure and trustworthy' AI development See omnystudio.com/listener for privacy information.

Duration:00:19:43

Closing the $1 trillion women’s health gap

1/26/2024
While it’s a known fact that women, on average, live longer than men, a recent report unveils a nuanced reality—women also spend more of their lives grappling with poor health. This week on “The Top Line,” Ayla Ellison, editor-in-chief of Fierce Healthcare and Life Sciences, explores the root causes behind this disparity and the multifacted nature of the women’s health gap. She's joined by one of the lead authors of the report, Valentina Sartori, Ph.D., and a contributor to the report, Kelle Moley, M.D. The report highlights that addressing the women’s health gap and investing in women’s health could inject $1 trillion into the economy annually by 2040, and Dr. Sartori explains why that number could be a significant underestimation. While the report provides a clear understanding of the challenges, it also sheds light on viable pathways to close the women’s health gap and create a future where women not only live longer but lead healthier lives. To learn more about the topics in this episode: Closing the women’s health gap: A $1 trillion opportunity to improve lives and economiesWhite House launches new initiative aimed at investing in women's health researchOrganon finally offers a larger pharma model for women's health. But 'one company can't do it by itself'CMS unveils new model to support Medicaid agencies in offering whole-person maternal healthMenopause care is still a largely untapped market. Here's why investors and startups should dive in See omnystudio.com/listener for privacy information.

Duration:00:20:20

A closer look at the bounty of new drug approvals in 2023

1/19/2024
At Fierce Pharma, the arrival of a new year is synonymous with the release of our annual special report on drug approvals. This week on “The Top Line,” Fierce Pharma’s Eric Sagonowsky and Kevin Dunleavy, both instrumental in creating the special report, are breaking down the numbers and sharing key insights into the landscape of drug approvals in 2023. To learn more about the topics in this episode: 2023 drug approvals: After a down year, FDA signs off on a bounty of new meds, including 7 from Pfizer2022 drug approvals: After Aduhelm fiasco, FDA endorsements drop to 372021 drug approvals: In a year dominated by COVID, biopharma managed to deliver 55 new drugsSee omnystudio.com/listener for privacy information.

Duration:00:12:46

The year in biotech

12/22/2023
This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. To learn more about the topics in this episode: Biotechs end year 'trading for nothing' as investors mull 'what is IPO-able today?'Fierce Biotech Layoff Tracker 2023Editor's Corner—When ASCO dueled with the world's biggest pop star, Swift Biotech was ready for itAlzheimer's meds are here. But for the Down syndrome community, it's still the 1980s See omnystudio.com/listener for privacy information.

Duration:00:08:39

[Sponsored] Addressing the evolving needs of pharma for CDx development

12/19/2023
Paul Beresford and Lou Welebob of Agilent Technologies discuss how partnerships are vital in addressing the evolving needs of pharma for complex diagnostics and CDx development. Discussions center around the importance of working with pharmaceutical companies to drive medical innovation and improve patient outcomes, helping to speed up the process of bringing the right treatments to the right patients at the right time. Topics discussed include the importance of broadening technological focus on immunohistochemistry, such as bridging into digital biology and imaging as well as multiplexing. Spatial biology is touched upon, specifically looking at how spatial profiling can be used to determine cell proximity within the tumor microenvironment, potentially correlated to drug efficacy. Looking ahead, both speakers point to the potential to use machine learning in key areas such as the development of assays for use across laboratories globally. To discover the full range of insights from life sciences, diagnostics and applied chemical markets specialist Agilent Technologies, listen to the full podcast. See omnystudio.com/listener for privacy information.

Duration:00:19:47

A closer look at the Fierce 50

12/15/2023
Earlier this year, Fierce Healthcare, Fierce Pharma and Fierce Biotech recognized 50 individuals and companies that are pushing the industry forward. The Fierce 50 honorees range from tech innovators to researchers developing novel therapies to providers on the frontlines of changing care. This week on "The Top Line," senior editor Paige Minemyer sat down with staff writers Dave Muoio and Anastassia Gliadkovskaya as well as senior editor Heather Landi to discuss a few of the honorees in more detail. To learn more about the topics in this episode: The Fierce 50 of 2023 See omnystudio.com/listener for privacy information.

Duration:00:30:44

Turning down the toxicity of nature’s most powerful antifungal

12/8/2023
The antifungal agent Amphotericin B is highly effective against a wide range of deadly fungi and resistance is rare, even after decades of use. But it comes with a virtual guarantee of kidney damage, earning it the nickname “Ampho-terrible.” Now, a better alternative might be on the way. Fierce Biotech Research’s Helen Floersh spoke with Martin Burke, M.D., Ph.D., a chemistry professor and researcher at the University of Illinois and the founder of antifungal startup Sfunga Therapeutics, to get the story behind the new drug’s design, its path to the clinic and how it could influence the next generation of antimicrobials. To learn more about the topics in this episode: Potent new drug has all the power of nature's strongest antibiotic, without the toxicity See omnystudio.com/listener for privacy information.

Duration:00:27:47

Fiercest Women in Life Sciences, meet the Fierce 50

12/1/2023
In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. Join Deputy Editor Andrea Park and Senior Editor Annalee Armstrong as they reflect on the inspiring stories of the women who made this year’s list. To learn more about the topics in this episode: 2023's Fiercest Women in Life SciencesThe Fierce 50 of 2023 Fierce 50 Awards Gala See omnystudio.com/listener for privacy information.

Duration:00:11:15

Exploring Alzheimer’s breakthroughs, Leqembi's potential and what comes next

11/17/2023
This episode of "The Top Line" is dedicated to Alzheimer’s disease, exploring the latest treatments and what lies ahead. In the first segment, Fierce Pharma’s Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. Next, Fierce Biotech’s Annalee Armstrong interviews Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They explore the pioneering work being done in Alzheimer's research and discuss the latest breakthroughs. In the third segment, Fierce Pharma’s Eric Sagonowsky talks with Reisa Sperling, M.D., who is leading a research team investigating whether Leqembi holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. To learn more about the topics in this episode: With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnestAfter winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous versionEisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drugEisai launches 'digital business' Theoria to build out a dementia ecosystem for patientsEisai, Biogen's injectable Leqembi clears toxic protein in Alzheimer's disease. What about safety?Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammationVoyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipelineAcumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active See omnystudio.com/listener for privacy information.

Duration:00:18:44

A look at psychedelics and the next frontier of mental healthcare

11/10/2023
In this episode of “The Top Line,” we explore the next potential wave of mental health therapy: psychedelics. Fierce Biotech's Max Bayer sits down with Scott Aaronson, M.D., a seasoned clinician and psychiatrist with over 30 years of experience in the field. They discuss how psychedelics might be used in the treatment of conditions such as depression, substance addiction, PTSD, anorexia, and more. They also examine the obstacles developers face as they advance their studies. To learn more about the topics in this episode: MDMA approval filing nears after drug hits again in phase 3, showing consistent PTSD improvementsEarly clinical data on psilocybin in anorexia point Compass to potential new opportunityOtsuka adopts new Mindset, dropping $59M to buy Canadian psychedelic biotechSee omnystudio.com/listener for privacy information.

Duration:00:17:14

Exploring the promise of earlier Alzheimer's treatment

11/3/2023
While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. To learn more about the topics in this episode: Eisai, Biogen's injectable Leqembi clears toxic protein in Alzheimer's disease. What about safety?'The Top Line': Leqembi's full approval and the future of Alzheimer's treatmentWith full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest See omnystudio.com/listener for privacy information.

Duration:00:13:15

A look at the FDA's Aduhelm approval and the potential for regulatory bias

10/27/2023
In this episode of “The Top Line,” we delve into the FDA's controversial approval of Aduhelm, a drug for Alzheimer's disease, despite an independent advisory committee's resounding rejection. The decision has sparked questions about potential bias within the regulatory body. Genevieve Kanter, Ph.D., a professor at the USC Sol Price School of Public Policy, joins Fierce's Kevin Dunleavy to discuss the implications of a study published in July in JAMA Health Forum, which found the FDA's propensity to favor positive panel recommendations. They explore the impact of this potential bias on drug development and public health. See omnystudio.com/listener for privacy information.

Duration:00:15:15

Leqembi's full approval and the future of Alzheimer's treatment

10/19/2023
In this episode of "The Top Line," Fierce's Fraiser Kansteiner engages in a conversation with Alexander Scott, senior vice president of integrity at Eisai, to discuss the full approval of Leqembi and what it means for Eisai and, most importantly, for Alzheimer's patients. To learn more about the topics in this episode: With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnestAfter winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous versionEisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drugEisai launches 'digital business' Theoria to build out a dementia ecosystem for patientsSee omnystudio.com/listener for privacy information.

Duration:00:16:36

Unraveling Alzheimer's disease treatments and a look ahead

10/13/2023
In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation. They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease. To learn more about the topics in this episode: With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active See omnystudio.com/listener for privacy information.

Duration:00:28:46

[Sponsored] Modeling patient insights to make the most of clinical trials

10/5/2023
“Essentially, this allows our clinical researchers to improve the chances of success for the trial leading to faster, more efficient drug development… Ultimately, this is going to benefit patients.” Greg Lever is speaking about the use of flexible modeling to allow real-time changes to be made to clinical trial design and processes. As a Director within the IQVIA Applied Data Science Center, and with over a dozen years of experience in the field, Greg knows the importance of data and advanced analytics in generating accurate patient insights to underpin key trial decision-making. By making clinical trials more patient friendly, he states, the more likely it is that research organizations will be able to attract and retain the participants they need to bring life-saving treatments to patients. In this podcast, Greg outlines how modeling can be used to enhance the entire patient journey, from the initial giving of informed consent right through to the trial’s close. Host: Julia Douthart Producer: Matt Rickman Sponsored by IQVIA See omnystudio.com/listener for privacy information.

Duration:00:11:56